Clinical Pharmacokinetics

, Volume 43, Issue 11, pp 725–732 | Cite as

Effect of Rifampicin on the Pharmacokinetics of Fluconazole in Patients with AIDS

  • Duangchit Panomvana Na Ayudhya
  • Nawarat Thanompuangseree
  • Somsit Tansuphaswadikul
Original Research Article



To study the effect of rifampicin on the pharmacokinetics of fluconazole and on clinical outcomes of fluconazole treatment in patients with AIDS-related cryptococcal meningitis.


Forty Thai patients with AIDS and cryptococcal meningitis, of whom 20 had been receiving oral rifampicin for at least 2 weeks to treat tuberculosis.


Patients were treated for cryptococcal meningitis with amphotericin 0.7 mg/kg/day for 14 days followed by fluconazole 400 mg/day, which was reduced to 200 mg/day once culture of cerebrospinal fluid (CSF) became negative. Patients with tuberculosis received oral rifampicin 600 mg/day at night. Blood samples were collected from the first 12 patients in each group and pharmacokinetic parameters for fluconazole were calculated. CSF samples were collected by lumbar puncture and monitored for eradication of Cryptococcus neoformans.


Concomitant administration of rifampicin with fluconazole resulted in significant changes in the pharmacokinetic parameters of fluconazole, including a 39% increase in elimination rate constant, 28% shorter elimination half-life, 22% decrease in area under the concentration-time curve, 17% decrease in maximum concentration and 30% increase in clearance (p < 0.05). Different fluconazole regimens did not affect the extent of change in the elimination rate constant. Although serum concentrations of fluconazole during the time that patients received rifampicin concomitantly with fluconazole 200 mg/day were generally lower than the minimum inhibitory concentration for C. neoformans, there were no significant differences in clinical outcomes between the two groups to date (p = 0.792).


Coadministration of rifampicin with fluconazole caused significant changes in the pharmacokinetic parameters of fluconazole. Long-term monitoring for recurrence rates of cryptococcal meningitis is required to assess the clinical significance of this interaction.


  1. 1.
    Grant SM, Clissold SP. Fluconazole: a review of its pharmaco-dynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877–916PubMedCrossRefGoogle Scholar
  2. 2.
    Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658–90PubMedCrossRefGoogle Scholar
  3. 3.
    Levy RH, Thummel KE, Trager WF, et al. Metabolic drug interactions. Philadelphia (PA): Lippincott Williams & Wilkins, 2000Google Scholar
  4. 4.
    Coker RJ, Tomlinson D, Parkin J. Interaction between fluconazole and rifampicin. BMJ 1990; 301: 818PubMedCrossRefGoogle Scholar
  5. 5.
    Apseloff G, Hilligoss DM, Gardner MJ. Induction of fluconazole metabolism by rifampicin: in vivo study in humans. J Clin Pharmacol 1991; 31: 358–61PubMedGoogle Scholar
  6. 6.
    Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990; 12 Suppl. 3: S327–33PubMedCrossRefGoogle Scholar
  7. 7.
    Nicolau DP, Crowe HM, Nightingale CH. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995; 29: 994–6PubMedGoogle Scholar
  8. 8.
    Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 Suppl. 3: S318–26PubMedCrossRefGoogle Scholar
  9. 9.
    Danson B, Trapp RG. Basic and clinical biostatistics. Singapore: McGraw Hill, 2001: 132–60Google Scholar
  10. 10.
    Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28(4): 363–6PubMedGoogle Scholar
  11. 11.
    RSTRIP II. Version 2.0. Salt Lake City (UT): MicroMath Scientific Software, 1995Google Scholar
  12. 12.
    Rowland M, Tozer T. Clinical pharmacokinetics: concepts and applications. Baltimore (MD): Lea & Febiger, 1995Google Scholar
  13. 13.
    Aller AI, Martin-Mazuelos E, Lozano F. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44: 1544–8PubMedCrossRefGoogle Scholar
  14. 14.
    Pfaller MA, Zhang J, Messer SA. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from United States and Africa. Antimicrob Agents Chemother 1999; 43: 169–71PubMedCrossRefGoogle Scholar
  15. 15.
    Lamaestro BM, Piatek M. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915–28CrossRefGoogle Scholar
  16. 16.
    Van der Horst C, Saag MS, Cloud GA. Treatment of cryptococccal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15–21PubMedCrossRefGoogle Scholar
  17. 17.
    Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17: 837–42PubMedCrossRefGoogle Scholar
  18. 18.
    Dismukes WE. Management of cryptococcosis. Clin Infect Dis 1993; 17 Suppl. 2: S507–12PubMedCrossRefGoogle Scholar
  19. 19.
    Caver PL. Invasive fungal infections. In: Pharmacotherapy: a pathophysiological approach. Stamford (CT): Appleton & Lange, 1999: 1839–66Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Duangchit Panomvana Na Ayudhya
    • 1
  • Nawarat Thanompuangseree
    • 2
  • Somsit Tansuphaswadikul
    • 3
  1. 1.Department of Clinical Pharmacy, Faculty of Pharmaceutical SciencesChulalongkorn UniversityBangkokThailand
  2. 2.Department of PharmacySuratthani HospitalSuratthaniThailand
  3. 3.Department of MedicineBamrajnaradura HospitalNonthaburiThailand

Personalised recommendations